359 related articles for article (PubMed ID: 30182859)
1. Neuroregeneration in Parkinson's Disease: From Proteins to Small Molecules.
Sidorova YA; Volcho KP; Salakhutdinov NF
Curr Neuropharmacol; 2019; 17(3):268-287. PubMed ID: 30182859
[TBL] [Abstract][Full Text] [Related]
2. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
3. GDNF family ligands: a potential future for Parkinson's disease therapy.
Mickiewicz AL; Kordower JH
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):703-11. PubMed ID: 21838676
[TBL] [Abstract][Full Text] [Related]
4. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
7. GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson's Disease.
Renko JM; Voutilainen MH; Visnapuu T; Sidorova YA; Saarma M; Tuominen RK
Front Neurol Neurosci Res; 2020 Nov; 1():100004. PubMed ID: 33479704
[TBL] [Abstract][Full Text] [Related]
8. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.
Voutilainen MH; Arumäe U; Airavaara M; Saarma M
FEBS Lett; 2015 Dec; 589(24 Pt A):3739-48. PubMed ID: 26450777
[TBL] [Abstract][Full Text] [Related]
10. Neurotrophic factors for the treatment of Parkinson's disease.
Chiocco MJ; Harvey BK; Wang Y; Hoffer BJ
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S321-8. PubMed ID: 18267258
[TBL] [Abstract][Full Text] [Related]
11. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
Youdim MB; Kupershmidt L; Amit T; Weinreb O
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
[TBL] [Abstract][Full Text] [Related]
12. BDNF as a Promising Therapeutic Agent in Parkinson's Disease.
Palasz E; Wysocka A; Gasiorowska A; Chalimoniuk M; Niewiadomski W; Niewiadomska G
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32050617
[TBL] [Abstract][Full Text] [Related]
13. Neurotrophic factors for the treatment of Parkinson's disease.
Sullivan AM; Toulouse A
Cytokine Growth Factor Rev; 2011 Jun; 22(3):157-65. PubMed ID: 21689963
[TBL] [Abstract][Full Text] [Related]
14. Neurotrophic Factors in Parkinson's Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Ferreira RN; de Miranda AS; Rocha NP; Simoes E Silva AC; Teixeira AL; da Silva Camargos ER
Curr Med Chem; 2018; 25(31):3682-3702. PubMed ID: 29532753
[TBL] [Abstract][Full Text] [Related]
15. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R; Gash DM
J Neurol; 1998 Nov; 245(11 Suppl 3):P35-42. PubMed ID: 9808338
[TBL] [Abstract][Full Text] [Related]
16. Nanodelivery of therapeutic agents in Parkinson's disease.
Lafuente JV; Requejo C; Ugedo L
Prog Brain Res; 2019; 245():263-279. PubMed ID: 30961870
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
Du Y; Zhang X; Tao Q; Chen S; Le W
Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
[TBL] [Abstract][Full Text] [Related]
18. Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.
Domanskyi A; Saarma M; Airavaara M
Hum Gene Ther; 2015 Aug; 26(8):550-9. PubMed ID: 26176331
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
Francardo V; Schmitz Y; Sulzer D; Cenci MA
Exp Neurol; 2017 Dec; 298(Pt B):137-147. PubMed ID: 28988910
[TBL] [Abstract][Full Text] [Related]
20. Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies.
Chmielarz P; Saarma M
Pharmacol Rep; 2020 Oct; 72(5):1195-1217. PubMed ID: 32700249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
